Placebo to Ciprofloxacin DPI (BAYQ3939)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchiectasis
Conditions
Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Trial Timeline
Jan 12, 2016 → Mar 17, 2016
NCT ID
NCT02661438About Placebo to Ciprofloxacin DPI (BAYQ3939)
Placebo to Ciprofloxacin DPI (BAYQ3939) is a pre-clinical stage product being developed by Novartis for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02661438. Target conditions include Bronchiectasis, Pulmonary Disease, Chronic Obstructive.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02661438 | Pre-clinical | Completed |
Competing Products
20 competing products in Bronchiectasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| AZD9668 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD5069 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD0292 | AstraZeneca | Phase 2 | 52 |
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin DPI (BAYQ3939) + Placebo | Novartis | Phase 3 | 77 |
| Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo | Novartis | Phase 3 | 77 |
| QBW251 + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin (Cipro, BAYQ3939) + Placebo | Novartis | Phase 2 | 52 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Aztreonam lysine | Gilead Sciences | Approved | 84 |
| AZLI | Gilead Sciences | Phase 2 | 51 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Itepekimab (SAR440340) + Placebo | Sanofi | Phase 2 | 51 |
| CSL787 + Placebo | CSL | Phase 1 | 32 |
| CSL787 + Placebo | CSL | Phase 2 | 51 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 74 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Group A + Group B | Bayer | Pre-clinical | 20 |
| BAY85-8501 + Placebo | Bayer | Phase 2 | 49 |